Maruho Co., Ltd.
Cutanea Life Sciences, Inc.

Maruho acquires Cutanea Life Sciences, Inc., U.S.A. Cutanea to become a wholly-owned subsidiary of Maruho.

Mr. Koichi Takagi, President and CEO of Maruho Co., Ltd, headquartered in Kita-ku, Osaka, Japan, announced today the acquisition of Cutanea life Sciences (CLS), a privately held dermatology development company based in Villanova, Pennsylvania U.S.A. Mr. Takagi stated that the acquisition of CLS represents an important step in building Maruho's infrastructure and capabilities in the United States.

Maruho, founded in 1915 in Osaka, Japan, is committed to advancing "Excellence in Dermatology". Maruho's long term vision aims to provide innovative pharmaceutical products to treat a variety of skin diseases in the global market place.

CLS, founded in 2005 is an early stage development company specializing in novel patent protected pharmaceuticals to treat skin diseases in the U.S. Currently CLS has three novel proprietary technology programs in development designed to offer alternative treatment approaches for several unmet medical conditions including rosacea and HPV (warts).

Both organizations are aligned in a common purpose to provide innovative solutions to treat unmet medical needs in the therapeutic space. Mr.Takagi, Maruho's CEO stated: "The CLS acquisition offers Maruho a unique opportunity to establish a foundation in the United States leveraging experienced management and a viable product pipeline." Mr. Bitterman, President and CEO of CLS, remarked: "Maruho brings a unique strategic vision along with a commitment to capital infusion to the United States, critically important to helping advance dermatology practice in the U.S.

Maruho is a leader in the development and commercialization of dermatological products in Japan. With the acquisition of CLS, Maruho expects to leverage CLS's know-how in new drug development and benefit from CLS' network in the U.S. dermatology market. Maruho intends to further enhance its development pipeline in the U.S. and effectively utilize both organization's strengths to promote new development projects and strengthen human resource capabilities, eventually creating a fully integrated marketing-development dermatology company in the U.S.

Contact Japan:

Mr. Junichi Hamada

Phone: 81(Japan)-6-6371-8837

Email: hamada_bai@mii.maruho.co.jp

Contact USA:

Mr. Robert Bitterman

Phone 1(USA)-484-568-0105

Email: rbitterman@cutanealife.com

Overview of CLS

1) Company name: Cutanea Life Sciences, Inc.

2) Location: Villanova, PA, U.S.A.

3) President & CEO: Robert J. Bitterman

4) Establishment: 2005; private venture funded

5) Accounting period: January to December

6) Business description: Development of pharmaceuticals in the field of dermatology